The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
Official Title: An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment
Study ID: NCT01894256
Brief Summary: This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow eligible study patients continued access to olaparib after the PK phase and will provide additional safety data.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Brussels (Jette), , Belgium
Research Site, Edegem, , Belgium
Research Site, Leuven, , Belgium
Research Site, Liege, , Belgium
Research Site, Wilrijk, , Belgium
Research Site, Herlev, , Denmark
Research Site, København Ø, , Denmark
Research Site, Bordeaux, , France
Research Site, Dijon, , France
Research Site, Amsterdam, , Netherlands
Research Site, Maastricht, , Netherlands
Research Site, Newcastle Upon Tyne, , United Kingdom
Research Site, Surrey, , United Kingdom
Name: Anitra Fielding
Affiliation: AstraZeneca Senior Research Physician
Role: STUDY_DIRECTOR
Name: Christian Rolfo
Affiliation: UZ Antwerpen
Role: PRINCIPAL_INVESTIGATOR